Sanofi

The European Commission has approved the first and only medicine for children aged 1-11 with eosinophilic esophagitis (#EoE). We’re proud to offer a treatment option that has the potential to improve the standard of care for children living with this chronic, progressive disease. Learn more about the news: https://lnkd.in/eUtjGA3b    Regeneron  

Did you know Respiratory Syncytial Virus (#RSV) can turn a family's world upside down in just a few days?  For most babies, RSV disease usually causes mild, cold-like symptoms. But in some cases, it can lead to more serious illnesses. As we mark #RSVAwarenessWeek in Europe, it's time to recognize the unseen battles that parents may face when a child contracts a severe form of RSV disease. The sleepless nights, the worry and the struggle to keep up with everyday life: it’s a tough reality. The #ResQFamily study by EFCNI - European Foundation for the Care of Newborn Infants uncovers just how families are managing these challenges. Curious about what they found? Read the full report: https://lnkd.in/e9itnGwm 

What does it take to create life-changing treatments? For Lana Vishneva, it’s all about connecting the dots. Just like creating a mosaic, Lana understands how individual pieces come together to form something meaningful ✨ 👩🔬 As one of our Product Managers, she brings our vision to life by blending research, patient insights, and team collaboration to develop treatments. Connecting with patients, listening to their stories, and witnessing the real difference her work makes is what drives her every day. Learn more about Lana's journey: https://spkl.io/6048fr65Y #WeNeverSettle #IgnitingPotential #RareDisease

Our CEO, Paul Hudson, reflects on our strong Q3, pushed forward by the momentum of our launches of innovative medicines and vaccines. Learn more about our Q3 2024 Results: https://spkl.io/6041fRCVf #SanofiResults

Our Q3 2024 results are now available. Learn more: https://spkl.io/6046fRCTw #SanofiResults

Positive late-breaking results from our phase 3 study in chronic spontaneous urticaria (CSU), are being presented at #ACAAI24. These results show the potential for our investigational medicine to provide a new option for people suffering from uncontrolled CSU. Learn more: https://spkl.io/6043fR2iR

As we commemorate October as Inclusion month, we look back at the vibrant celebrations from Pride Month earlier this year. At #Sanofi, inclusion is more than just a celebration—it's a daily commitment to creating a workplace where every voice is heard, and every individual is empowered. This month, we continue our efforts to honor the diversity that makes us stronger together.   If you want to belong to a workplace where being who you are is second nature, consider joining us. See career opportunities here: https://lnkd.in/eMp6zZC Surabhi Kaul Nikunj Doshi

Ready for your shot of knowledge? ☕ #Flu season is here, and what better way to dive into the topic than to test the expertise of our Sanofi family? 📚 We took to the office and asked our employees some quick questions about influenza. Reckon they’re Flu-ent? 🤔 Check out our video to find out! Way to go Sebastian Benitez Hisham A Fyyaz Eugénie Martel Yiran Wang Alejandra Torres Mejia MD, MSc

Today, we entered an agreement with Orano Med  focused on accelerating the development of next-generation radioligand therapies.    This news marks an important step forward in our commitment to expanding our oncology presence and our mission to find solutions for difficult-to-treat cancers.    Read our press release: https://lnkd.in/eqr6eZm6

“I always knew I wanted to do something meaningful to make a difference, not only for me, but to the world.” From Gabriela Pacheco Lalia Prado’s start as a mathematician and artistic roller skater in Brazil, she’s gone from intern to country lead in Chile and is now a launch lead in Iberia, building a major project plan from scratch, surrounded by a team of creative thinkers. ⤵️ #PursueProgress #DiscoverExtraordinary #AllWell